WhatsApp：+447349736496
Telegram:+8618049650067

Product Information

I. Basic Properties & Mechanism of Action

Cagrilintide (developmental code AM833) is a synthetically derived, long-acting acylated amylin analog with the molecular formula C₁₉₄H₃₁₂N₅₄O₅₉S₂ and an approximate molecular weight of 4409 Da. Its structure incorporates N-terminal fatty acid modification (e.g., C20 diacid) to enhance albumin-binding properties, extending its half-life to 159–195 hours and enabling once-weekly administration. As a dual agonist of amylin receptors (AMYR) and calcitonin receptors (CTR), it modulates appetite and energy metabolism by activating hypothalamic satiety centers, delaying gastric emptying, and suppressing glucagon secretion.

II. Clinical Research Findings

Weight Management & Metabolic Effects

1. Monotherapy Efficacy:

   • In Phase II trials, 4.5 mg dosing for 26 weeks reduced body weight by an average of 10.8% in obese patients.

   • Effects were dose-dependent, with higher doses (2.4–4.5 mg) demonstrating significantly greater weight loss vs. placebo (P<0.001).

2. Combination Therapy:

   • Paired with GLP-1 receptor agonist semaglutide in the combination CagriSema, Phase III trials showed:

     • 68-week treatment achieved 15.6–22.7% weight reduction in diabetes patients with obesity;

     • Among non-diabetic overweight/obese participants, 53.6% achieved ≥20% weight loss, with 19.3% reaching ≥30%;

     • Concurrent improvements in HbA1c (-2.18%), blood pressure, and lipid profiles.

     • 

III. Safety & Tolerability

• Primary Adverse Events: Mild-to-moderate gastrointestinal incidents (nausea, vomiting, diarrhea; ~72.5% incidence), primarily during dose escalation and typically transient.

• No Major Cardiovascular Risks: No clinically significant increases in heart rate abnormalities or neuropsychiatric adverse events observed in trials.

• Contraindications: Not to be used in patients with personal/family history of medullary thyroid carcinoma (potential CTR activation risk).

1. IV. Research Applications & Development

   1. Indication Focus:

      • Currently prioritized for obesity (BMI≥30 kg/m²) and type 2 diabetes with overweight/obesity management;

      • Phase III REDEFINE trials evaluating long-term cardiometabolic benefits (2025 update).

   2. Optimization Pathways:

      • Investigating synergy with GLP-1/GIP dual-target agents;

      • Developing oral formulations (e.g., Amycretin) and monthly injectables (e.g., MET-233i) to improve adherence.

Company Introduction

csxj Technology Co., Ltd. is an innovative technology enterprise specializing in the field of weight management and metabolic health. We are dedicated to the R&D, production, and supply of high-quality solutions based on cutting-edge biotechnology for the global market, with core expertise in GLP-1-related products and high-purity active ingredients. Leveraging robust scientific capabilities and a stringent quality management system, we consistently deliver safe, efficient weight management and metabolic products and materials to meet diverse client needs. Driven by technological innovation and a customer-centric approach, we collaborate with partners to advance the health industry and empower global users in achieving healthier lifestyles.

Introduction to transportation
We usually use a safe shipping method and do not require you to go through any customs clearance. Free shipping to your address without worrying about any customs issues. We have a professional customs clearance team that 100% guarantees the safe delivery of your package. If anything happens to your package, we promise to send it again for free. Enjoy the second free reissue policy. We can safely ship large parcels of 1000-2000kg/time without any customs issues. Our mission is always to put safety first.

Product Certificates